AtriCure, Inc. (ATRC) - Stock Analysis
Last updated: Mar 15, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
AtriCure exhibits strong short-term growth supported by 16% revenue increase in Q3, positive EBITDA growth, cash flow improvement, clinical pipeline advancements, and strong technical breakout despite near-term technical softness.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margin ⢠Negative annual earnings ⢠Low leverage ATRC combines strong gross margins, meaningful free cash flow and low leverage with persistent annual losses, high operating expenses, large intangibles and a demanding valuation, implying operational resilience but caution on profitability and price.
Price Behavior
Key Price Behavior Insights: ⢠Near-term support ⢠Resistance cluster ⢠Elevated volatility Support Level: $29.18 (psych $30.00) Resistance Level: $31.20â$33.00 Over the last month ATRC has fallen ~6% into the lower end of its range, trading near short-term support at $29.18 (psych $30.00) and below resistance at $31.20â$33.00, a short-term bearish signal unless it reclaims that band.
Sentiment & News
Key News Insights: ⢠Accelerating growth ⢠Reaffirmed guidance ⢠Institutional buying AtriCure posted 15% revenue growth for 2025, beat Q4 estimates with $0.06 EPS, reaffirmed 2026 revenue guidance of 12â14%, and showed improving profitability alongside rising analyst and institutional interest.
AI Summary
AtriCure appears to have moved from a development-stage spender to a credible growth-at-improving-margins story driven by focused device ramps and positive near-term EBITDA guidance, but that reârating is entirely conditional on flawless execution of product rollouts and binary clinical/PFA readouts. Investors should watch PFA firstâinâhuman outcomes and whether consumable attach rates/pricing holdâfailures there or trial delays would likely cause sharp valuation compression.
Description
AtriCure develops, manufactures and sells surgical systems and devices used to ablate cardiac tissue and intercostal nerves, serving hospitals and cardiac centers in the United States and internationally. Its portfolio includes radiofrequency and cryoablation systems, epicardial appendage occlusion and suture-based closure solutions, and a range of supporting instruments and disposables for electrophysiology and cardiac surgery. The company distributes products through a mix of independent distributors and direct sales teams and is headquartered in Mason, Ohio; it was incorporated in 2000.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 12 | Jan 19 | ATRC | AtriCure, Inc. | AtriCure exhibits strong short-term growth supported by 16% revenue increase in Q3, positive EBITDA growth, cash flow improvement, clinical pipeline advancements, and strong technical breakout despite near-term technical softness. | Closed | +3.8% |